SLV 320Potent and selective A1 antagonist CAS# 251945-92-3 |
- Thrombin Receptor Agonist Peptide
Catalog No.:BCC3950
CAS No.:137339-65-2
- TFLLR-NH2
Catalog No.:BCC3948
CAS No.:197794-83-5
- AY-NH2
Catalog No.:BCC3949
CAS No.:352017-71-1
- ML161
Catalog No.:BCC3642
CAS No.:423735-93-7
- AC 55541
Catalog No.:BCC3951
CAS No.:916170-19-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 251945-92-3 | SDF | Download SDF |
PubChem ID | 9953065 | Appearance | Powder |
Formula | C18H20N4O | M.Wt | 308.38 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 50 mM in ethanol | ||
Chemical Name | 4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexan-1-ol | ||
SMILES | C1CC(CCC1NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4)O | ||
Standard InChIKey | RBZNJGHIKXAKQE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective adenosine A1 receptor antagonist (Ki values are 1, 200, 398 and 3981 nM at human A1, A3, A2A and A2B receptors respectively). Suppresses cardiac fibrosis and attenuates albuminuria, without effect on blood pressure in animal models of chronic renal failure. Orally active. |
SLV 320 Dilution Calculator
SLV 320 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.2428 mL | 16.2138 mL | 32.4275 mL | 64.855 mL | 81.0688 mL |
5 mM | 0.6486 mL | 3.2428 mL | 6.4855 mL | 12.971 mL | 16.2138 mL |
10 mM | 0.3243 mL | 1.6214 mL | 3.2428 mL | 6.4855 mL | 8.1069 mL |
50 mM | 0.0649 mL | 0.3243 mL | 0.6486 mL | 1.2971 mL | 1.6214 mL |
100 mM | 0.0324 mL | 0.1621 mL | 0.3243 mL | 0.6486 mL | 0.8107 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- AM 1172
Catalog No.:BCC7675
CAS No.:251908-92-6
- Dynamin inhibitory peptide
Catalog No.:BCC1034
CAS No.:251634-21-6
- Isohomoarbutin
Catalog No.:BCN7612
CAS No.:25162-30-5
- Loline
Catalog No.:BCN2003
CAS No.:25161-91-5
- Acevaltrate
Catalog No.:BCN7127
CAS No.:25161-41-5
- 5-Chloro-2-nitrobenzoic acid
Catalog No.:BCC8743
CAS No.:2516-95-2
- Tesaglitazar
Catalog No.:BCC7828
CAS No.:251565-85-2
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- SU 16f
Catalog No.:BCC7639
CAS No.:251356-45-3
- Urotensin II (human)
Catalog No.:BCC5796
CAS No.:251293-28-4
- Crebanine
Catalog No.:BCN5117
CAS No.:25127-29-1
- FRATide
Catalog No.:BCC5821
CAS No.:251087-38-4
- A 205804
Catalog No.:BCC3944
CAS No.:251992-66-2
- AZD7545
Catalog No.:BCC4294
CAS No.:252017-04-2
- Fmoc-D-Threoninol
Catalog No.:BCC2702
CAS No.:252049-02-8
- Fmoc-Lys(Me2)-OH
Catalog No.:BCC2567
CAS No.:252049-10-8
- Tertiapin-Q
Catalog No.:BCC5740
CAS No.:252198-49-5
- 1-Cinnamoylpyrrole
Catalog No.:BCN4006
CAS No.:252248-89-8
- 9,9'-O-Isopropyllidene-isolariciresinol
Catalog No.:BCN1474
CAS No.:252333-71-4
- Isotaxiresinol 9,9'-acetonide
Catalog No.:BCN4663
CAS No.:252333-72-5
- Lucidadiol
Catalog No.:BCN7142
CAS No.:252351-95-4
- Lucidal
Catalog No.:BCN3206
CAS No.:252351-96-5
- Ethyl orsellinate
Catalog No.:BCN4662
CAS No.:2524-37-0
- Apelin-36 (human)
Catalog No.:BCC5910
CAS No.:252642-12-9
The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.[Pubmed:17558436]
Br J Pharmacol. 2007 Aug;151(7):1025-32.
BACKGROUND AND PURPOSE: Myocardial fibrosis is an unwanted effect associated with chronic renal failure. The adenosine system is involved in cardiac and renal function. Therefore, we investigated the novel selective adenosine A(1) receptor antagonist SLV320 focusing on its potential in preventing cardiomyopathy in rats with 5/6 nephrectomy. EXPERIMENTAL APPROACH: Male Sprague-Dawley rats were allocated to 4 groups of 12 rats each: 5/6 nephrectomy (5/6 NX), 5/6 NX plus SLV320 (10 mg kg(-1) d(-1) mixed with food), sham and sham plus SLV320. Study duration was 12 weeks, blood pressure was assessed repeatedly. At study end kidney function was assessed, blood samples and hearts were taken for histology/immunohistochemistry. Pharmacological properties of SLV320 were assessed using receptor binding and enzyme assays and in vivo. KEY RESULTS: SLV320 is a selective and potent adenosine A(1) antagonist in vitro (Ki=1 nM) with a selectivity factor of at least 200 versus other adenosine receptor subtypes. Functional A(1) antagonism was demonstrated in vivo. In rats with 5/6 NX SLV320 significantly decreased albuminuria by about 50%, but did not alter glomerular filtration rate (GFR). SLV320 normalized cardiac collagen I+III contents in 5/6 NX rats. SLV320 prevented nephrectomy-dependent rise in plasma levels of creatinine kinase (CK), ALT and AST. Blood pressure did not differ between study groups. CONCLUSION: SLV320 suppresses cardiac fibrosis and attenuates albuminuria without affecting blood pressure in rats with 5/6 nephrectomy, indicating that selective A(1) receptor antagonists may be beneficial in uraemic cardiomyopathy.